Gwen Verlinghieri
Family · Sharon Hill, PANPI 1376784397
Payments from drug & device makers
Across 504 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$3K
- Johnson & Johnson$1K
- AbbVie$959
- Janssen Products, LP$725
- Otsuka America Pharmaceutical, Inc.$492
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$1081%
- Food & beverage$11,00795%
- Education$4144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 208 | $4,118 |
| Gilead | 101 | $2,654 |
| Johnson & Johnson(2 entities) | 37 | $1,033 |
| AbbVie | 46 | $959 |
| Janssen Products, LP | 9 | $725 |
| Otsuka America Pharmaceutical, Inc. | 25 | $492 |
| Theratechnologies Inc. | 11 | $316 |
| Merck | 15 | $222 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Napo Pharmaceuticals Inc | 7 | $153 |
| Alkermes, Inc. | 8 | $149 |
| Vanda Pharmaceuticals Inc. | 7 | $119 |
| Novo Nordisk | 6 | $116 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| GSK | 2 | $44 |
| Indivior Inc. | 2 | $44 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $22 |
| Qiagen, LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Pfizer | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,529 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 483 | $1,832,533 |
| JulucaDolutegravir/Rilpivirine | 91 | $312,287 |
| DovatoDolutegravir Sodium/Lamivudine | 85 | $244,759 |
| TivicayDolutegravir Sodium | 70 | $149,674 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 24 | $125,361 |
| DescovyEmtricitabine/Tenofov Alafenam | 57 | $121,372 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 16 | $57,018 |
| VraylarCariprazine Hcl | 27 | $31,360 |
| TrulicityDulaglutide | 28 | $22,307 |
| RexultiBrexpiprazole | 15 | $20,769 |
| OzempicSemaglutide | 23 | $20,249 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,267 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,249 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 13 | $8,191 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $2,654 | $2,079,266564 claims |
| Viiv Healthcare CompanyJuluca, Dovato, Tivicay | $4,118 | $706,720246 claims |
| Janssen Products, LPSymtuza | $725 | $57,01816 claims |
| AbbVieVraylar | $959 | $31,36027 claims |
| Lilly USA, LLCTrulicity | $16 | $22,30728 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $492 | $20,76915 claims |
| Novo NordiskOzempic | $116 | $20,24923 claims |
| Boehringer IngelheimSpiriva Respimat, Synjardy | $22 | $16,26433 claims |
| GSKBreo Ellipta, Incruse Ellipta, Arnuity Ellipta | $44 | $16,13849 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $154 | $96628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Sharon Hill
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.